Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase

Area of Science:

• Endocrinology
• Metabolic Diseases
• Medical Devices

Background:

• Optimized multiple daily injection (MDI) therapy is a standard for diabetes management.
• Sensor-augmented pump (SAP) therapy integrates continuous glucose monitoring with insulin pump technology.
• Understanding the transition and long-term effects of switching to SAP is crucial for diabetes care optimization.

Purpose of the Study:

• To evaluate the impact of transitioning from optimized MDI to SAP therapy over 6 months.
• To assess the sustained glycemic benefits of SAP therapy over 18 months.
• To determine the safety and efficacy of SAP therapy in a real-world clinical setting.

Main Methods:

• A 6-month, single-crossover design was employed as part of the STAR 3 study.
• 420 participants who completed a 1-year randomized trial were included.
• The primary outcome measured was the change in glycated hemoglobin A1C (HbA1C) levels in the crossover group.

Main Results:

• Initial A1C levels were lower in the group continuously using SAP compared to the crossover group (7.4% vs. 8.0%).
• Participants switching to SAP showed a significant A1C reduction to 7.6% within 3 months (P < 0.001).
• This A1C decrease was significant and sustained in both adult and pediatric populations (P < 0.05).

Conclusions:

• Transitioning from optimized MDI to SAP therapy facilitates rapid and safe reductions in A1C.
• The glycemic improvements achieved with SAP therapy are maintained for at least 18 months.
• SAP therapy represents an effective strategy for enhancing glycemic control in individuals with diabetes.